EKOS Corporation, headquartered in the United States, is a leading player in the biotechnology industry, specialising in innovative solutions for medical and pharmaceutical applications. Founded in 2001, the company has achieved significant milestones, including the development of advanced drug delivery systems that enhance therapeutic efficacy. With a strong presence in North America and Europe, EKOS Corporation focuses on core products such as ultrasound-assisted drug delivery and catheter-based therapies. These unique offerings set the company apart by improving patient outcomes and minimising procedural risks. Recognised for its commitment to quality and innovation, EKOS has established a solid market position, contributing to advancements in minimally invasive treatments.
How does EKOS Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
EKOS Corporation's score of 97 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
As of the latest available data, EKOS Corporation does not report specific carbon emissions figures, indicating a lack of disclosed emissions data. However, the company is part of a corporate family relationship with Boston Scientific Corporation, from which it inherits climate commitments and initiatives. EKOS Corporation's climate strategy is influenced by Boston Scientific's sustainability efforts, which include various reduction initiatives and targets. Although specific reduction targets for EKOS are not detailed, the overarching commitments from Boston Scientific may guide EKOS's approach to managing its carbon footprint. The absence of direct emissions data suggests that EKOS Corporation is in the early stages of formalising its climate commitments. The company may benefit from leveraging the established frameworks and targets set by Boston Scientific, particularly in relation to the Science Based Targets initiative (SBTi) and other sustainability frameworks. In summary, while EKOS Corporation currently lacks specific emissions data and reduction targets, its affiliation with Boston Scientific Corporation positions it to adopt and implement effective climate strategies in the future.
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
EKOS Corporation's Scope 3 emissions, which increased by 28% last year and decreased by approximately 7% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
EKOS Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.